Researchers discovered that a natural compound called sclareol may help treat a serious liver condition called MASH (metabolic dysfunction-associated steatohepatitis), where fat builds up in the liver and causes damage. In laboratory and animal studies, sclareol reduced fat accumulation, inflammation, and scarring in the liver by activating protective pathways in the body. The compound also improved blood sugar and cholesterol levels while reducing harmful molecules that damage cells. While these early results are encouraging, human studies are still needed to confirm whether sclareol could become a useful treatment for people with fatty liver disease.
The Quick Take
- What they studied: Whether a natural plant compound called sclareol could help treat a serious liver disease where fat builds up and damages the liver (MASH)
- Who participated: Laboratory liver cells and laboratory mice fed a high-fat diet to mimic the human disease. No human participants were involved in this study.
- Key finding: Sclareol reduced fat accumulation, inflammation, and liver scarring in mice with the disease, and improved their blood sugar and cholesterol levels compared to untreated mice
- What it means for you: This is early-stage research showing promise for a potential new treatment, but it’s not ready for human use yet. People with fatty liver disease should continue following their doctor’s current recommendations while researchers work on testing this compound in humans.
The Research Details
The researchers used two different approaches to test sclareol. First, they grew human liver cells in dishes and exposed them to high levels of fatty acids (which mimic what happens in fatty liver disease), then treated them with sclareol to see what happened. Second, they created a mouse model of the disease by feeding mice a high-fat diet and giving them a chemical that damages the liver. After the mice developed the disease, they gave some mice sclareol (at two different doses) while others received no treatment, and compared the results after six weeks.
This two-step approach (starting with cells, then moving to animals) is standard in early drug research. It allows scientists to understand how a compound works at the cellular level before testing it in living organisms. The mouse model is important because it closely mimics how the disease develops in humans, making the results more relevant than cell studies alone.
The researchers measured many different markers of liver health, including fat content, inflammation, scarring, blood sugar, cholesterol, and the activity of specific proteins involved in the disease process.
Testing in both cells and animals provides stronger evidence than either approach alone. The cell studies show the basic mechanism of how sclareol works, while the animal studies show whether those mechanisms actually improve the disease in a living system. This combination helps researchers understand if a compound is worth pursuing for human testing.
This is a well-designed preliminary study with multiple measurements and both laboratory and animal testing. However, it has important limitations: no human participants were involved, the sample size for animal studies wasn’t specified, and the results haven’t been confirmed by other research groups yet. The study was published in a peer-reviewed journal, which means other scientists reviewed it before publication, adding credibility.
What the Results Show
In liver cells treated with sclareol, the compound reduced harmful molecules called reactive oxygen species and nitric oxide, which damage cells and cause inflammation. It also reduced the expression of genes that tell cells to make and store fat, helping prevent fat accumulation.
In mice with the disease, sclareol improved multiple markers of liver health. The mice that received sclareol had lower blood sugar levels, better cholesterol levels, and less liver damage compared to untreated mice. When researchers examined the livers under a microscope, they found that sclareol reduced fat deposits, inflammation, and scarring—all signs of improvement.
The compound worked by activating a protein called AMPK, which acts like a master switch for cellular health. When AMPK is activated, it turns down the genes that make fat and turns up the genes that protect against inflammation and scarring. Sclareol also reduced the activity of inflammatory pathways that drive the disease forward.
Interestingly, sclareol changed the types of bacteria and their products in the mice’s intestines, which may have contributed to the liver improvements. This suggests the compound works through multiple pathways in the body, not just directly on the liver.
The study found that sclareol reduced markers of cell death (apoptosis) in the liver, meaning it helped protect liver cells from dying. It also improved the overall structure and appearance of liver tissue under the microscope. The compound appeared to work at multiple dose levels, though the higher dose (10 mg/kg) showed slightly better results than the lower dose (5 mg/kg) in some measurements.
This is the first study to examine sclareol specifically for MASH treatment. However, sclareol is a natural compound found in plants that has been studied for other health benefits. Previous research has shown that activating AMPK and reducing inflammation are effective strategies for treating fatty liver disease, so the mechanisms sclareol uses align with what scientists already know works. The results are consistent with how other anti-inflammatory and antioxidant compounds have performed in similar animal studies.
This study only tested sclareol in laboratory cells and mice—not in humans. Animal studies don’t always translate to human results because our bodies are more complex. The exact dose that would be safe and effective in humans is unknown. The study didn’t compare sclareol to existing treatments for fatty liver disease, so we don’t know if it would be better, worse, or similar to current options. The sample size for the animal studies wasn’t clearly reported, which makes it harder to assess the strength of the findings. Finally, this is a single study, and the results need to be confirmed by other research groups before we can be confident in the findings.
The Bottom Line
Based on this early research, sclareol shows potential as a future treatment for MASH, but it is NOT ready for human use. People with fatty liver disease should not attempt to use sclareol supplements based on this study. Instead, focus on proven approaches: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, and work with your doctor on a treatment plan. If you have fatty liver disease, discuss all treatment options with your healthcare provider.
This research is most relevant to scientists and doctors developing new treatments for fatty liver disease. People with MASH or other forms of fatty liver disease should be aware of this promising research but should not change their current treatment without talking to their doctor. People interested in natural compounds and plant-based medicine may find this research interesting as an example of how traditional plant compounds are being studied with modern science.
This research is in the very early stages. If sclareol moves forward, it would typically take 5-10 years of additional testing before it could potentially be available as a treatment for humans. This includes more animal studies, safety testing, and eventually human clinical trials.
Want to Apply This Research?
- Users with fatty liver disease can track liver health markers that their doctor monitors: weight, waist circumference, blood sugar levels (if diabetic), cholesterol levels, and liver enzyme levels from blood tests. Record these measurements monthly or as recommended by their healthcare provider.
- Implement and track the proven lifestyle changes that this research supports: reduce intake of high-fat and high-sugar foods, increase physical activity to at least 150 minutes per week, maintain a healthy weight, and limit alcohol. Use the app to log meals, exercise, and weight to monitor progress toward these goals.
- Set up monthly reminders to record weight and waist circumference. Schedule quarterly check-ins with your doctor to monitor blood work (liver enzymes, blood sugar, cholesterol). Track dietary changes and exercise consistently. Create a dashboard showing progress on these evidence-based interventions while staying informed about emerging treatments like sclareol through your healthcare provider.
This research is preliminary and has only been tested in laboratory cells and mice. Sclareol is not approved for human use and should not be used to treat fatty liver disease without medical supervision. The findings do not constitute medical advice. People with fatty liver disease should consult their healthcare provider before making any changes to their treatment plan or starting any new supplements. This study does not replace established medical treatments or lifestyle modifications recommended by doctors. Always discuss new research findings with your healthcare provider before considering them for personal use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.